Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively
Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively
Xoma以500万美元的价格收购了与LadRx的两项资产（包括阿里莫洛莫和阿多柔比星）相关的特许权使用费和里程碑权，分别用于孤儿病尼曼-皮克病C型和2期肿瘤学
Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively
Xoma以500万美元的价格收购了与LadRx的两项资产（包括阿里莫洛莫和阿多柔比星）相关的特许权使用费和里程碑权，分别用于孤儿病尼曼-皮克病C型和2期肿瘤学
资讯热榜
更新时间